Melanoma antigens

Details Melanoma antigens Melanoma antigens

C - Chemistry, Metallurgy

07

K

C07K 14/705 (2006.01) A61K 39/00 (2006.01) C07K 7/06 (2006.01) C07K 14/47 (2006.01) C07K 16/30 (2006.01) C12N 15/12 (2006.01) C12Q 1/68 (2006.01) G01N 33/574 (2006.01)

Patent

CA 2722364

The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognose a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

Affiliated with

Also associated with

Rating

Melanoma antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanoma antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma antigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1663400